[How I manage B cell lymphoma patients treated with CD19 specific CAR-T cell throughout whole-process management]

Zhonghua Xue Ye Xue Za Zhi. 2022 Mar 14;43(3):197-202. doi: 10.3760/cma.j.issn.0253-2727.2022.03.003.

[Article in Chinese]

Authors

W B Qian¹, H Liu¹

Affiliation

¹ Department of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China.

PMID: 35405776
PMCID: PMC9072073
DOI: 10.3760/cma.j.issn.0253-2727.2022.03.003

No abstract available

MeSH terms

Antigens, CD19*
Humans
Immunotherapy, Adoptive / adverse effects
Lymphoma, B-Cell* / etiology
Lymphoma, B-Cell* / therapy
Receptors, Antigen, T-Cell
T-Lymphocytes

Substances

Antigens, CD19
Receptors, Antigen, T-Cell

Grants and funding

基金项目：浙江省重点研发计划（2021C03117）；国家血液系统疾病临床医学研究中心2020年度开放课题重点项目（2020ZKZC01）；国家自然科学基金面上项目（82170219）